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Abstract 
Background: Myelodysplastic syndrome (MDS), a heterogeneous group of hematopoietic malignancy, has been 
shown to present different cytogenetic abnormalities, risk factors, and clinico-hematological features in different 
populations and geographic areas. Herein, we determined the cytogenetic spectrum and clinico-hematological fea-
tures of Iranian MDS patients for the first time.
Methods: This prospective cross-sectional study was conducted on 103 patients with MDS in Ahvaz, southwest of 
Iran, from 2014 to 2018. Clinical presentations, complete blood counts (CBC), and bone marrow (BM) biopsy samples 
were assessed. Perls’ staining was used to evaluate BM iron storage. The cytogenetic evaluation was performed using 
the conventional G banding method on the BM.
Results: Patients’ median age was 62.3 (ranged from 50–76), and the majority were male (72.8%). The most com-
mon clinical symptom at the time of admission was fatigue (n = 33) followed by pallor (n = 27). The most common 
subgroup was MDS-Multi Lineage Dysplasia (MDS-MLD) (n = 38, 36.8%), followed by MDS-Single Lineage Dysplasia 
(MDS-SLD) (n = 28, 18.4%). A normal karyotype was observed in 59 patients (57.3%), while 44 patients (42.7%) had 
cytogenetic abnormalities. Trisomy 8 (+ 8) was the most common cytogenetic abnormality (n = 14) followed by del 
17p (n = 9) and monosomy 7 (− 7) (n = 7). Twelve patients (11.65%) were transformed to AML.
Conclusion: Our data betokened that among our MDS patients, Trisomy 8 is the predominant cytogenetic abnor-
mality, and MDS-MLD and MDS-SLD are the most common of subtypes. Noteworthy, the male: female ratio was 
slightly higher in Iran than in previous reports from other parts of the world. Our study is the first report of the clinical, 
hematological, and cytogenetic spectrum of MDS patients in Iran
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Introduction
Myelodysplastic Syndromes (MDSs) are a group of 
hematopoietic disorders characterized by ineffective 
hematopoiesis, dysplasia of hematopoietic cells, and 
cytopenia in one or more blood cell lineages [1]. MDS 
generally occurs de novo; however, a small number of 
MDSs are secondary to radiation and/or chemotherapy 
Open Access
*Correspondence:  omidkianis@gmail.com
2 Department of Hematology and Blood Banking, School of Allied 
Medicine, Iran University of Medical Sciences, Tehran, Iran
Full list of author information is available at the end of the article
Page 2 of 7Paridar et al. Mol Cytogenet           (2021) 14:24 
exposure. Pathophysiology of the disease includes multi-
step processes involving chromosomal abnormalities 
and/or genetic aberrations [2]. In the United States, MDS 
incidence is 3–4 per 100,000 annually and increases with 
age [3]. Usually, this disease is more prevalent in men 
than women, except for the 5q deletion subgroup, which 
is more common in women [4]. The disease course is 
very variable, ranging from an indolent to an aggressive 
state. However, it is often associated with an increased 
risk of acute myeloid leukemia (AML) transformation 
and a short survival rate [5]. Diagnosis of MDS transpires 
via scrutiny of the peripheral blood smear (PBS) and the 
bone marrow (BM). Pancytopenia and single or multilin-
eage dysplasia are observed in the PB, whereas less than 
20% blasts and hematopoietic cells dysplasia are detected 
in the BM. Based on the 2016 classification of the World 
Health Organization (WHO), MDS comprises six sub-
groups, including MDS with multilineage dysplasia 
(MDS-MLD), MDS with single lineage dysplasia (MDS-
SLD), MDS with ring sideroblasts (MDS-RS), MDS with 
excess blasts (MDS-EB − 1 and 2), MDS with isolated del 
(5q), and unclassifiable MDS (MDS-U) [6].
Cytogenetic abnormalities such as amplifications, dele-
tions, and translocations have been detected in about 
50% of patients with de novo MDS and 80% of patients 
with secondary MDS, as well [7]. Evaluation of cytoge-
netic abnormalities is useful in the diagnosis of MDS 
and crucial in determining the prognosis [8]. Indeed, the 
chromosomal abnormality type is one of the most impor-
tant factors employed in the MDS Revised International 
Prognostic Scoring System (R-IPSS) [9]. Patient progno-
sis helps determine the disease’s clinical course and plays 
a vital role in establishing the patient’s therapeutic plan 
[10].
There are many reports from western countries in 
terms of cytogenetic profiles of MDS patients. However, 
clinical symptoms, cytogenetic abnormalities, and the 
disease’s pathophysiology are dissimilar in different pop-
ulations and vary greatly in different geographic areas. 
Therefore, the current study aimed to determine the 
cytogenetic spectrum and clinico-hematological features 
of MDS patients in the Khuzestan province, southwest of 




This prospective cross-sectional study was conducted 
on 103 patients with MDS referred to Shafa Hospital in 
Ahvaz, southwest of Iran, from 2014 to 2018. Patients 
diagnosed as de novo MDS according to their clinical 
and hematological findings were included in the study. 
Notably, we excluded patients with cytopenia due to 
other non-malignant disorders and patients with a his-
tory of chemotherapy or radiotherapy. All patients were 
diagnosed and classified according to the classification of 
myeloid neoplasms and acute leukemia of the 2016 revi-
sion of the World Health Organization [6]. This study was 
approved by the Ethics Committee of Ahvaz Jundishapur 
University of Medical Sciences. Signed consent forms 
were received from all the patients prior to participation 
in the study.
Hematological assessments
Following the clinical examination, complete blood 
counts (CBC) were performed, and PBS was scrutinized. 
Patients suspected of having MDS were subjected to fur-
ther evaluation by BM biopsy samples obtained from the 
posterior superior iliac spine. According to the manufac-
turer’s protocol, assessment of Iron was performed on 
the BM using the Perls’ stain kit (Sigma-Aldrich).
Cytogenetic analysis
The cytogenetic evaluation was performed using a con-
ventional G banding method on the BM samples. First, 
BM cells were cultured for 24 h in 5 ml of Marrowmax 
medium, 20% FBS, 2 mg L-glutamine, and 100 ml/U 
penicillin/streptomycin. Afterward, a total of 50 μl of col-
cemid (10 μg/ml) was added to the culture medium, and 
cells were incubated for 20 min at 37 ºC. Following this, a 
hypotonic potassium chloride solution was added to the 
cells which were incubated for 25 min at 37 ºC. CELLS 
were then fixed with methanol:acetic acid (3:1), and slides 
of metaphase chromosomes were prepared in a humidi-
fied and controlled temperature environment. Metaphase 
chromosomes (at least 20 metaphases) were banded 
using the Giemsa trypsin banding (GTG) method, and 
karyotypes were defined according to the International 
System for Human Cytogenetic Nomenclature (ISCN) 
2013 criteria.
Statistical analysis
Data are displayed as mean values, while the stand-
ard error of the mean was shown using error bars 
(Mean ± SEM). GraphPad Prism (Version 8.0.1.244, San 




Among 300 patients originally referred to the hospital, 
a total of 103 patients were diagnosed as de novo MDS 
according to their clinical and hematological tests and 
hence were included in the study. Patients’ median age 
was 62.3 years (50–76), and the majority of patients were 
of male (72.8%). The mean levels of hemoglobin (Hb), 
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platelets (plt), and white blood cells (WBC) were 9.9 g/dl, 
103 ×  103/μl, and 3.4 ×  103/μl; respectively (Table 1).
More than 75% of the patients presented hypercellu-
lar BM. Moreover, iron storage was increased in 86 cases 
(83.5%) (Table  1). The major clinical symptom at the 
time of admission was fatigue (n = 33) followed by pal-
lor (n = 27), easy bruising and bleeding (n = 20), recur-
rent infections (n = 19), and bone pain (n = 4). Finally, 
a total of twelve patients (11.65%) were transformed to 
AML. Based on FAB classification, 4, 6, and 2 patients 
progressed to AML-M0, AML-M1, and AML-M2, 
respectively.
Patients classification
The patients were classified into different subgroups 
according to the 2016 revision of the WHO classification. 
The most common subgroup was MDS-MLD (n = 38, 
36.8%) followed by MDS-SLD (n = 28, 18.44%). However, 
the rarest subgroup was MDS-RS (n = 3, 2.91%) (Table 2).
Patients karyotypes
Concerning the karyotypes of the patients, a total of 59 
patients (57.28%) presented a normal karyotype, while 
the remaining 44 patients (42.72%) had cytogenetic 
abnormalities (Fig. 1a). Patients with abnormal karyotype 
showed different types of abnormalities. Single, double 
and complex abnormalities were observed in 32 (72.7%), 
9 (20.5%) and 3 (6.5%) patients; respectively (Fig. 1b). The 
distribution of normal and abnormal karyotypes among 
MDS subgroups is demonstrated in Fig. 1c. On the other 
hand, the most common cytogenetic abnormality among 
the 44 MDS patients was Trisomy 8 (+ 8) (n = 14), fol-
lowed by del 17p (n = 9) and monosomy 7 (− 7) (n = 7) 
(Fig.  2). The prevalence and distribution of the chro-
mosomal abnormalities in MDS patients are detailed in 
Fig. 2.
Patients prognosis
The patients’ prognosis was assessed according to 
the Revised International Prognostic Scoring System 
[R-IPSS]. Results showed that a total of 68 patients 
(66%) were considered as good or very good prognosis 
(Table 3). Moreover, 26 cases (25.2%) showed an interme-
diate prognosis. However, a poor prognosis was observed 
in 9 cases (8.7%), while none of the patients showed very 
poor prognosis (Table 3).
Discussion
MDS is a heterogeneous clonal disorder associated 
with ineffective hematopoiesis, reduced blood cells, and 
hematopoietic cells’ dysplasia. Generally, MDS is known 
as a preleukemic disorder and is considered an elderly 
disease. Indeed, the mean age of patients in our study was 
66 years, with a range of 50–76 years, which is similar 
Table 1 Patients’ characteristics
WBC white blood cells, ANC absolute neutrophil count, BM bone marrow
Gender Male 75 (72.81%)
Female 28 (27.19%)
Age (years) Median (range) 62.3 (50–76)
Work history Agriculturist 23 (22.33%)
Petroleum worker 7 (6.79%)
Truck driver 5 (4.85%)
Others 68 (66%)
Hemoglobin (g/dl) Median ± SD 9.9 ± 1.1
Platelet (×  103/μl) Median ± SD 103 ± 20
WBC (×  103/μl) Median ± SD 3.4 ± 0.5
ANC (×  103/μl) Median ± SD 1.6 ± 0.3
BM cellularity Hypercellular 78 (75.73%)
Normocellular 18 (17.47%)
Hypocellular 7 (6.8%)
BM Iron storage Increased 86 (83.5%)
Decreased 0
Normal 17 (16.5%)
Table 2 Patients’ subgroups based on WHO Classification 2016
MDS-MLD MDS with multilineage dysplasia, MDS-SLD MDS with single lineage dysplasia, MDS-EB MDS with excess blasts, MDS-RS MDS with ring sideroblasts, MDS-U 
MDS unclassifiable
Subgroups Number of patients Normal cytogenetics Abnormal 
cytogenetics
MDS-MLD 38 (36.89%) 22 16
MDS-SLD 28 (18.44%) 17 11
MDS-EB MDS- EB-1 15 (14.56%) 11 4
MDS-EB -2 11 (10.67%) 5 6
MDS with isolated del(5q) 4 (3.88%) 0 4
MDS-RS 3 (2.91%) 1 2
MDS-U 4 (3.88%) 3 1
Page 4 of 7Paridar et al. Mol Cytogenet           (2021) 14:24 
to MDS in the US population (67 years) [11], and close 
to Turkey (69 years) [12] and European countries such 
as Germany (70 years) [13] and Poland [14] (70 years). 
On the other hand, our results are significantly differ-
ent from those of East Asian countries such as China 
(49 years) [15], India (42, 45, and 55 years) [16–18], and 
Japan (76 years) [19]. Most of the patients were farmers 
or worked in petroleum jobs. It is worth noting that most 
of the farmers in the southwest regions of Iran, where 
our study was conducted, are exposed to pesticides. The 
association of pesticide exposure and MDS incidence was 
recently confirmed in a meta-analysis study [20]. Moreo-
ver, many investigators reported that petroleum workers 
exposed to benzene had an important MDS risk factor 
[21, 22]. The male to female ratio was 2.6:1, which was 
clearly higher than those reported from the US (1.9: 1) 
[11], Korea (1.7: 1) [23], China (1.3: 1) [15], and Pakistan 
(1.7: 1) [24]. In Iranian culture, women do not work as 
much as men, especially the high-risk jobs, which might 
explain the higher male: female ratio in our study com-
pared to other reports.
The mean hemoglobin level in our study on southwest 
Iranian patients was 9.9 g/dl, which is similar to that 
obtained in Turkey (9 g/dl) [12] and Greece (9.5 g/dl) 
[25]. However, our hemoglobin data are higher than those 
obtained in Pakistan (7.7 g/dl), China (6.3 g/dl) [15], Sin-
gapore (7.7 g/dl) [26], and India (6.84 g/dl) [18]. The dif-
ference may be due to the higher percentage of males in 
our study and the fact that Iran implements a national 
iron supplementation program. On the other hand, the 
mean platelet counts in our study was 103 ×  103/μl, which 
is similar to those obtained by Lau et  al. in Singapore 
(101 ×  103/μl) [26]. However, our data on platelets counts 
are higher than those obtained by Chen et  al. in China 
(42 ×  103/μl) [15], Ehsan et  al. in Pakistan (60 ×  103/μl), 
and Chaubey et al. in India (85 ×  103/μl)[18]. Noteworthy 
Fig. 1 Prevalence of the cytogenetic abnormalities observed in MDS patients. a Prevalence of normal and abnormal karyotypes among MDS 
patients. b Types of abnormalities among patients with abnormal karyotype. c Distribution of normal and abnormal karyotypes among MDS 
subgroups
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that even higher platelet counts were reported in Turkey 
(163 ×  103 μl) [12] and Greece (158 ×  103/μl) [25].
Although our study included patients from the 2014 
to 2018 period, all patients were re-classified according 
to the 2016 revision of the World Health Organization 
classification of myeloid neoplasms and acute leukemia 
[6]. Our data showed that the most common MDS sub-
group was MDS-MLD (36.9%), followed by MDS-SLD 
(18.4%). These results are in line with those of Haase 
et  al. in Germany [27] and Rashid et  al. in Pakistan 
[28], who reported that MDS-MLD is the most com-
mon subtype (27.6% and 52.1%, respectively). More-
over, Pozdnyakova et  al. in the USA [11] and Li et  al. 
in China [29] reported that MDS-MLD was the most 
common subgroup (Respectively 32.2% and 44%) fol-
lowed by MDS-EB-I. In contrast, Chauby et al. reported 
MDS-SLD as the most common type of MDS in India 
[18]. The aforementioned differences might be due to 
the different ethnicity, population of the study, and/or 
sensitivity of the applied laboratory assay.
Cytogenetic abnormalities play a substantial role in the 
pathogenesis of MDS and are key factors in the diagnosis, 
classification, and prognostic scoring of the disease. How-
ever, the pathogenesis of MDS is still not well understood 
in Iran. The environmental, occupational, and genetic 
factors in Iran’s southwest region are very different from 
western countries. This would affect the pathogenesis of 
MDS and may cause various chromosomal abnormali-
ties, different frequencies, and patterns of MDS subtypes. 
Chromosomal abnormalities were observed in 42.7% of 
the patients, in accordance to other studies conducted in 
different parts of the world such as in Pakistan (42.3%) 
[28], the United States (44.5%) [11], Germany (49.8%) 
[27], Tunisia (51%) [30], and India (47.5%) [18]. However, 
this was less than what was found in China (67.5%) [29]. 
In particular, 41.7%, 29.5%, and 28.8% of the reported 
chromosomal abnormalities were related to copy number 
only, structural abnormalities, and concomitant occur-
rence of both, respectively [29]. Among patients with 
abnormal karyotypes, 72.7% had a single abnormality, 
20.5% had double abnormalities, while 6.8% had complex 
abnormalities (more than 3 abnormalities). The prognos-
tic score of the studied patients was assessed according 
to R-IPSS. Accordingly, more than 91.3% of patients had 
very good, good, and intermediate prognosis. However, 
the poor prognosis was observed in only 9 cases, and very 
poor prognosis was observed in none of the patients.
Fig. 2 The prevalence of chromosomal abnormalities in MDS 
patients




Cytogenetic abnormality Total MDS subtypes
MDS-SLD MDS-MLD MDS-EB-1 MDS-EB-2 MDS with del (5q) MDS-RS MDS-U




0 0 0 0 0
Good Normal 59 17 (60.7%) 22 (57.9%) 11 (73.3%) 5 (43.5%) 0 1 (33.3%) 3 (75%)




0 0 4 (100%) 0 0
Intermediate  + 8, + 19, del 7q, i(17q), other 
single/double abnormalities




0 2 (66.7%) 1 (25%)
Poor -7, inv (3), double includ-






5 (45.5%) 0 0 0
Very poor  > 3 abnormalities 0 0 0 0 0 0 0 0
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In this study, the most common chromosomal abnor-
mality was trisomy 8 (13.6% of all patients and 31.8% of 
patients with abnormal karyotype), followed by del 17p 
(8.7% of all patients and 20.5% of patients with abnormal 
karyotype). Trisomy 8 was observed in 10 patients as a 
single chromosomal abnormality, in 2 patients with dou-
ble chromosomal abnormalities, and in 2 patients with 
a complex karyotype. In accordance, Li et  al. in China 
[29] and Rashid et  al. in Pakistan [28] showed that the 
most common chromosomal abnormality was trisomy 
8. In contrast, the most common chromosomal abnor-
mality in Tunisia [30], Germany [27], Switzerland [31], 
Greece [25], and the United States [11] was − 5/del (5q). 
Our results showed that chromosomal abnormalities 
in Iranian MDS patients often include changes in the 
copy number (except for 2 cases), including deletion of 
all or part of a chromosome (e.g., del 17p or monosomy 
7) or gain of a chromosome (e.g., trisomy 8), while bal-
ance abnormalities (such as translocations) have a very 
low incidence in patients. The changes in copy numbers 
result in a change in the dosage of genes, which can lead 
to the inactivation of tumor suppressor genes and the 
activation of oncogenes by various mechanisms such 
as haploinsufficiency and loss of heterozygosity, thus 
playing an essential role in the initiation and progres-
sion of the disease. For instance, it has been shown that 
the CUX1 gene, expressed on chromosome 7, acts as a 
tumor suppressor gene in myeloid precursors, decreases 
in MDS (and AML) with − 7/del (7q), and is involved in 
the pathogenesis of the disease [32]. It is worth noting 
that MDS cells with trisomy 8 (+ 8) express high levels of 
antiapoptotic proteins and have high resistance to apop-
totic agents, such as gamma rays [33].
There has not been such a registry developed to capture 
the MDS epidemiology in Iran yet. So, we will be the pio-
neer to report the Clinico-Hematological and cytogenetic 
spectrum of adult myelodysplastic syndrome in addition 
to the plethora of scientific information that is already 
available in the western and eastern literature. It is worth 
mentioning that cytogenetics mainly aims to identify 
recurrent karyotypic alterations which are termed clonal 
chromosomal aberrations (CCAs), while non-clonal 
chromosome aberrations (NCCAs) might also play an 
intriguing role [34, 35]. Recently NCCAs have drawn 
more attention, so it would be interesting to include 
NCCA data for future studies, especially for patients who 
did not display clonal chromosome aberrations.
Conclusion
Our data indicated that MDS-MLD and MDS-SLD are 
the most common subtypes of MDS in Iran’s southwest 
region. In addition, Trisomy 8 was the most predominant 
cytogenetic abnormality. Moreover, our results showcased 
that the male: female ratio is slightly higher than previous 
reports from other parts of the world. This study represents 
the first report of the clinical, hematological, and cytoge-
netic spectrum of MDS patients in Iran. This study’s major 
limitations are that patients’ overall survival, treatment 
strategies, and response to treatment were not evaluated 
and suggested to be resolved in future studies.
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